INOVIO Launches Public Offering Under $300M Shelf, Adding Dilution Risk
INO is trading near its 52-week low of $0.95 (7.4% below the low).
Summary
INOVIO announced an underwritten public offering of common stock and warrants, tapping its recently effective $300M shelf registration. The size and terms are not yet disclosed, but the move signals urgent cash needs amid severe liquidity concerns and a stock trading near its 52-week low of $0.95. This follows the S-3 filing on July 2 and the Q1 10-Q highlighting a cash runway only into Q1 2027, with FDA skepticism on its lead drug. The offering is highly dilutive for a micro-cap biotech with a market cap around $85M, and the inclusion of warrants suggests weak demand. The shelf registration became effective July 10, and this is the first drawdown. Watch for the pricing terms in the prospectus supplement—a deep discount would confirm distress.
Updates
· SEC 424B5 — The offering consists of shares of common stock each accompanied by a warrant to purchase two shares, with warrants exercisable immediately and expiring five years from issuance. Piper Sandler is sole manager.
At the time of this announcement, INO was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.6M. The 52-week trading range was $0.95 to $2.98. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.